Among the receptor tyrosine kinase inhibitors, ponatinib (trade name Iclusig, previously AP24534), dasatinib, and sunitinib (previously known as SU11248) were the most potent drugs affecting the viability of liposarcoma cells lines irrespective of subtypes (Fig. 3a), and each is FDA approved for multiple other malignancies. This evidence concerns the gene NTRK1 and liposarcoma.